Status:
COMPLETED
Depression, Epinephrine, and Platelet Function
Lead Sponsor:
Emory University
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
Men and women who have suffered sexual and/or physical abuse before the age of 12 are at increased risk for anxiety and mood disorders, other serious psychiatric disorders, and likely medical illnesse...
Eligibility Criteria
Inclusion
- \-
Exclusion
- Individuals who are suicidal, psychotic, or with bipolar depression
- alcohol or substance abuse or
- regularly use medications which alter mood or blood vessel function (zolpidem or zalpelon, aspirin, nonsteroidal antiinflammatory drugs, sympatholytics, theophylline, central acting agonists, beta-blockers, coumadin, nitrates, triazolobenzodiazapines, or use steroids (testosterone-patch or pill form), use tryptophan or monoamine oxidase inhibitors (MAOIs),
- have narrow-angle glaucoma, liver disease,
- severe allergies (especially to antidepressants similar to escitalopram or desipramine)
- seizures, or a serious medical disorder (e.g. hypothyroidism) that is unstable or is untreated.
- Depressed patients with a prior history of severe adverse events associated with SSRIs or TCAs will not be accepted into the study.
Key Trial Info
Start Date :
February 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00166114
Start Date
February 1 2002
End Date
January 1 2009
Last Update
July 23 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University School of Medicine
Atlanta, Georgia, United States, 30322